Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

The essential SARS-CoV-2 3CL protease is of interest as a drug target. Here, the authors identify three 3CL inhibitors and characterize them both in vitro and with a cell-based assay, and they also present the inhibitor-bound 3CL crystal structures, which may allow for the design of improved compoun...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sho Iketani, Farhad Forouhar, Hengrui Liu, Seo Jung Hong, Fang-Yu Lin, Manoj S. Nair, Arie Zask, Yaoxing Huang, Li Xing, Brent R. Stockwell, Alejandro Chavez, David D. Ho
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/26f785c3852741599e99fcbeb5f6eb0e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:26f785c3852741599e99fcbeb5f6eb0e
record_format	dspace
spelling	oai:doaj.org-article:26f785c3852741599e99fcbeb5f6eb0e2021-12-02T14:25:02ZLead compounds for the development of SARS-CoV-2 3CL protease inhibitors10.1038/s41467-021-22362-22041-1723https://doaj.org/article/26f785c3852741599e99fcbeb5f6eb0e2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-22362-2https://doaj.org/toc/2041-1723The essential SARS-CoV-2 3CL protease is of interest as a drug target. Here, the authors identify three 3CL inhibitors and characterize them both in vitro and with a cell-based assay, and they also present the inhibitor-bound 3CL crystal structures, which may allow for the design of improved compounds.Sho IketaniFarhad ForouharHengrui LiuSeo Jung HongFang-Yu LinManoj S. NairArie ZaskYaoxing HuangLi XingBrent R. StockwellAlejandro ChavezDavid D. HoNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Sho Iketani Farhad Forouhar Hengrui Liu Seo Jung Hong Fang-Yu Lin Manoj S. Nair Arie Zask Yaoxing Huang Li Xing Brent R. Stockwell Alejandro Chavez David D. Ho Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
description	The essential SARS-CoV-2 3CL protease is of interest as a drug target. Here, the authors identify three 3CL inhibitors and characterize them both in vitro and with a cell-based assay, and they also present the inhibitor-bound 3CL crystal structures, which may allow for the design of improved compounds.
format	article
author	Sho Iketani Farhad Forouhar Hengrui Liu Seo Jung Hong Fang-Yu Lin Manoj S. Nair Arie Zask Yaoxing Huang Li Xing Brent R. Stockwell Alejandro Chavez David D. Ho
author_facet	Sho Iketani Farhad Forouhar Hengrui Liu Seo Jung Hong Fang-Yu Lin Manoj S. Nair Arie Zask Yaoxing Huang Li Xing Brent R. Stockwell Alejandro Chavez David D. Ho
author_sort	Sho Iketani
title	Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
title_short	Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
title_full	Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
title_fullStr	Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
title_full_unstemmed	Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
title_sort	lead compounds for the development of sars-cov-2 3cl protease inhibitors
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/26f785c3852741599e99fcbeb5f6eb0e
work_keys_str_mv	AT shoiketani leadcompoundsforthedevelopmentofsarscov23clproteaseinhibitors AT farhadforouhar leadcompoundsforthedevelopmentofsarscov23clproteaseinhibitors AT hengruiliu leadcompoundsforthedevelopmentofsarscov23clproteaseinhibitors AT seojunghong leadcompoundsforthedevelopmentofsarscov23clproteaseinhibitors AT fangyulin leadcompoundsforthedevelopmentofsarscov23clproteaseinhibitors AT manojsnair leadcompoundsforthedevelopmentofsarscov23clproteaseinhibitors AT ariezask leadcompoundsforthedevelopmentofsarscov23clproteaseinhibitors AT yaoxinghuang leadcompoundsforthedevelopmentofsarscov23clproteaseinhibitors AT lixing leadcompoundsforthedevelopmentofsarscov23clproteaseinhibitors AT brentrstockwell leadcompoundsforthedevelopmentofsarscov23clproteaseinhibitors AT alejandrochavez leadcompoundsforthedevelopmentofsarscov23clproteaseinhibitors AT daviddho leadcompoundsforthedevelopmentofsarscov23clproteaseinhibitors
_version_	1718391416022892544

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

Ejemplares similares